Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip

Take a brief audio tour around Scrip's Five Must-Know Things, this time covering key developments reported in the business week ended 25 September 2020.

Significant new data from ESMO, Pfizer's changing oncology strategy, and a critical drug pricing hearing in the US are among the items on the agenda in this episode. 

This and other Informa Pharma Intelligence podcasts are also now voice-accessible as a skill on Alexa smart speakers and the Alexa app, under the "Business and Finance" category. Just say “Alexa, Open Informa - Pharma Intelligence" and you can then ask for a specific podcast.

Stories mentioned in this episode:

(Also see "ESMO: A Tale Of Two CDK 4/6 Inhibitors With monarchE Success and Failure For PALLAS" - Scrip, 21 Sep, 2020.)

(Also see "ESMO: Pfizer's Lorbrena Makes Case To Claim ALK+ Lung Cancer CROWN" - Scrip, 20 Sep, 2020.)

(Also see "Amgen’s KRAS Inhibitor Shows Durability; Pivotal Data Possible This Year" - Scrip, 21 Sep, 2020.)

(Also see "Pfizer Oncology Pipeline Shows Pivot To Targeted Therapies" - Scrip, 22 Sep, 2020.)

(Also see "Why Is Congress Targeting These Six Medicines In Drug Price Hearing?" - Scrip, 23 Sep, 2020.)

 

 

 

 

Related Content

Topics

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel